Abeona Therapeutics (ABEO) Stock Price, Quote & News

Company Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based g...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 813 4701

Website: www.abeonatherapeutics.com

Address:

6555 Carnegie Avenue, 4th Floor, Cleveland, United States

acm20 Jan. 14 at 5:27 PM

$ABEO Maybe the bottom... just a guess. Higher lows the past few days, tightening up slightly.

0 · Reply

acm20 Jan. 14 at 3:35 PM

$ABEO Continuing to add at these prices. Caught a few just below $5 the other day.

0 · Reply

FitzCatalyst Jan. 14 at 1:54 PM

$ABEO need news

1 · Reply

TragicRain Jan. 14 at 12:43 PM

$ABEO - Doing a little "Happy Dance" - just because I have a feeling.....

1 · Reply

JimiJoJeeter Jan. 12 at 6:24 PM

$ABEO Hoping and expecting news of further patient treatments soon... This is a steal at $5.

1 · Reply

Filvul Jan. 12 at 5:38 PM

$ABEO whats happening??

1 · Reply

creditgoo Jan. 12 at 3:22 PM

$ABEO tehehe

0 · Reply

FitzCatalyst Jan. 9 at 7:44 PM

$ABEO started out promising

0 · Reply

Filvul Jan. 9 at 3:45 PM

$ABEO if they have opened manufacturing, we have to wait at least 25 days from now...

1 · Reply

commoncentsinvestor Jan. 9 at 3:38 PM

$ABEO Newcomers should be aware that ABEO has net cash of $3.82 per share. That means that at the current share price of $5.30, the actual cost per share for Zevaskyn and the rest of the company is only $1.48. If the company does anywhere near what they are expected to do in revenues, and a gross margin over 80%, somebody is going to make a lot of money investing in ABEO.

2 · Reply

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 15, 2025, 7:30 AM EST - 4 weeks ago

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

Dec 11, 2025, 7:30 AM EST - 4 weeks ago

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

Dec 8, 2025, 7:30 AM EST - 5 weeks ago

Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy

Nov 12, 2025, 2:52 PM EST - 2 months ago

Abeona Therapeutics Q3 2025: Strong Financials And Zevaskyn Launch Ahead

Nov 12, 2025, 12:11 PM EST - 2 months ago

Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:30 AM EST - 2 months ago

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

Nov 7, 2025, 7:30 AM EST - 2 months ago

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

Oct 30, 2025, 10:45 AM EDT - 2 months ago

Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)

Oct 20, 2025, 8:30 AM EDT - 3 months ago

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

Oct 13, 2025, 7:30 AM EDT - 3 months ago

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program

Oct 8, 2025, 7:30 AM EDT - 3 months ago

Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy

Aug 29, 2025, 7:30 AM EDT - 4 months ago

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Aug 19, 2025, 3:25 PM EDT - 5 months ago

Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript

Aug 15, 2025, 4:36 PM EDT - 5 months ago

Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevaskyn

Aug 14, 2025, 7:30 AM EDT - 5 months ago

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

Jul 29, 2025, 10:00 AM EDT - 6 months ago

AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients

Jul 15, 2025, 7:30 AM EDT - 6 months ago

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

Jul 14, 2025, 7:00 AM EDT - 6 months ago

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

TECH

Jul 2, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

Jul 1, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

Jun 30, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index

Jun 24, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

Jun 5, 2025, 5:48 AM EDT - 7 months ago

Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)

May 30, 2025, 8:46 AM EDT - 8 months ago

Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

May 16, 2025, 1:37 AM EDT - 8 months ago

Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript

May 15, 2025, 7:30 AM EDT - 8 months ago

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

May 14, 2025, 8:07 AM EDT - 8 months ago

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 8 months ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 8 months ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 12, 2025, 7:30 AM EDT - 8 months ago

Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million

Apr 30, 2025, 4:41 PM EDT - 9 months ago

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

Apr 29, 2025, 6:06 AM EDT - 9 months ago

US FDA approves Abeona's skin disorder therapy

Apr 29, 2025, 6:00 AM EDT - 9 months ago

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Apr 27, 2025, 8:30 AM EDT - 9 months ago

Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken +

DDD TKR KARO NNDM ORC PAA PAGP

Apr 21, 2025, 10:00 AM EDT - 9 months ago

Pz-Cel Has Massive Potential For RDEB Patients

Apr 12, 2025, 11:39 AM EDT - 9 months ago

Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher

Mar 20, 2025, 3:20 PM EDT - 10 months ago

Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 7:30 AM EDT - 10 months ago

Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Mar 4, 2025, 9:00 AM EST - 11 months ago

Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Jan 24, 2025, 12:40 PM EST - 1 year ago

Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued

Nov 14, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 12, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Nov 4, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Announces Participation in November Investor Conferences

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Oct 3, 2024, 8:09 AM EDT - 1 year ago

Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Aug 13, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

Aug 12, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

Jul 12, 2024, 4:59 PM EDT - 1 year ago

Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones

acm20 Jan. 14 at 5:27 PM

$ABEO Maybe the bottom... just a guess. Higher lows the past few days, tightening up slightly.

0 · Reply

acm20 Jan. 14 at 3:35 PM

$ABEO Continuing to add at these prices. Caught a few just below $5 the other day.

0 · Reply

FitzCatalyst Jan. 14 at 1:54 PM

$ABEO need news

1 · Reply

TragicRain Jan. 14 at 12:43 PM

$ABEO - Doing a little "Happy Dance" - just because I have a feeling.....

1 · Reply

JimiJoJeeter Jan. 12 at 6:24 PM

$ABEO Hoping and expecting news of further patient treatments soon... This is a steal at $5.

1 · Reply

Filvul Jan. 12 at 5:38 PM

$ABEO whats happening??

1 · Reply

creditgoo Jan. 12 at 3:22 PM

$ABEO tehehe

0 · Reply

FitzCatalyst Jan. 9 at 7:44 PM

$ABEO started out promising

0 · Reply

Filvul Jan. 9 at 3:45 PM

$ABEO if they have opened manufacturing, we have to wait at least 25 days from now...

1 · Reply

commoncentsinvestor Jan. 9 at 3:38 PM

2 · Reply

TragicRain Jan. 9 at 3:30 PM

$ABEO - is that a possible cup/handle being formed on the 10day...... Happy Happy Dance !

0 · Reply

TragicRain Jan. 9 at 3:00 PM

$ABEO - Happy Dance....

0 · Reply

FitzCatalyst Jan. 9 at 1:53 PM

$ABEO

0 · Reply

invest2021_now Jan. 8 at 5:33 PM

$ABEO added, patience!

0 · Reply

PsychTrades Jan. 8 at 4:58 PM

$ABEO adding on red

0 · Reply

creditgoo Jan. 8 at 4:56 PM

$ABEO turd stock

2 · Reply

acm20 Jan. 8 at 4:30 PM

$ABEO Biotech sector down today (XBI, IBB). Since no catalyst yet, we move with the sector. I continue to add at these prices.

0 · Reply

winding Jan. 8 at 3:39 PM

$ABEO I've been holding this stock since before approval and even made additional purchases along the way, which raised my average price, so I'm still in the red. If it drops below 5, I'm thinking of making one last buy. What do you all think? Are you feeling positive about it? I used to think it was a great stock before approval, but its performance since then has been really disappointing.

4 · Reply

FitzCatalyst Jan. 8 at 3:14 PM

$ABEO need news

1 · Reply

commoncentsinvestor Jan. 8 at 2:06 PM

$ABEO Small cap medical stocks are very vulnerable to short plays right after FDA approval and before they have proven marketability. But that's why they also present amazing opportunities for those getting in early if they do successfully market their product. ABEO has the huge advantage of being the only product that can do what it does AND $200M in cash to support its marketing program. I put the odds of success at at least 70% which makes the potential for gain far more than the potential for loss. So once their is just a hint of Zevaskyn success, the shorts will flee, the big boys will come in and the share price could easily triple or more.

0 · Reply

S144 Jan. 7 at 8:32 PM

$ABEO Short interest is 26%. That's a huge number .. What is going on here ? @alexpitti

5 · Reply

commoncentsinvestor Jan. 7 at 2:50 PM

$ABEO 50 cell and gene therapy leaders to watch in 2026 https://www.drugdiscoverytrends.com/50-cell-and-gene-therapy-leaders-to-watch-in-2026/

0 · Reply

Market Cap	276.37M
Revenue (ttm)	0.00
Net Income (ttm)	-63.73M
EPS (ttm)	N/A
PE Ratio	4.59
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.12

Volume	436,742
Avg Vol	1,805,488
Day's Range	N/A - N/A
Shares Out	54.19M
Stochastic %K	25%
Beta	1.12
Analysts	Strong Sell
Price Target	$20.64